Menu Search
Equities

Fresenius Medical Care AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FME:SWX

Fresenius Medical Care AG

Actions
  • Price (CHF)75.28
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.0906
Data delayed at least 15 minutes, as of Jun 25 2019 14:41 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Fresenius Medical Care AG had relatively flat revenues (19.45bn to 19.34bn), though the company grew net income 7.80% from 499.00m to 537.91m. A reduction in the selling, general and administrative costs as a percentage of sales from 16.43% to 16.25% was a component in the net income growth despite flat revenues.
Gross margin25.00%
Net profit margin4.62%
Operating margin7.60%
Return on assets2.86%
Return on equity5.41%
Return on investment3.66%
More ▼

Cash flow in EURView more

In 2024, cash reserves at Fresenius Medical Care AG fell by 241.90m. However, the company earned 2.39bn from its operations for a Cash Flow Margin of 12.34%. In addition the company used 84.94m on investing activities and also paid 2.57bn in financing cash flows.
Cash flow per share7.78
Price/Cash flow per share5.26
Book value per share44.67
Tangible book value per share-6.51
More ▼

Balance sheet in EURView more

Fresenius Medical Care AG has a Debt to Total Capital ratio of 42.95%, a lower figure than the previous year's 70.16%.
Current ratio1.36
Quick ratio0.9963
Total debt/total equity0.8088
Total debt/total capital0.4295
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)2.71%
Div growth rate (5 year)3.71%
Payout ratio (TTM)58.90%
EPS growth(5 years)-14.29
EPS (TTM) vs
TTM 1 year ago		9.18
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.